Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 8/20 | 0.41 |
| ▸ | BCR | P11274 | 8/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | BMI1 | P35226 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16740326 | 0.87 | BMI1 (0.49) | KCNH2SCN5ASCN9AABL1BCR | |
| SCHEMBL16740380 | 0.86 | BMI1 (0.52) | KCNH2SCN5ASCN9ADHFRBMI1 | |
| SCHEMBL16739749 | 0.85 | BMI1 (0.53) | KCNH2SCN5ASCN9ABRAFDHFR | |
| SCHEMBL16740249 | 0.85 | KCNH2 (0.47) | KCNH2SCN5ASCN9ABRAFABL1 | |
| SCHEMBL16740293 | 0.81 | TRPV1 (0.37) | DHODHBMI1 | |
| SCHEMBL16739623 | 0.80 | KCNH2 (0.51) | KCNH2SCN5ASCN9ABRAFABL1 | |
| SCHEMBL16740257 | 0.79 | KCNH2 (0.50) | KCNH2SCN5ASCN9ABRAFABL1 | |
| SCHEMBL16740062 | 0.79 | KCNH2 (0.50) | KCNH2SCN5ASCN9ABRAFABL1 | |
| SCHEMBL16739937 | 0.78 | KCNH2 (0.49) | KCNH2SCN5ASCN9ABRAFABL1 | |
| SCHEMBL18094403 | 0.78 | KCNH2 (0.49) | KCNH2SCN5ASCN9ABRAFABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | claimed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | claimed |
| EP-3071553-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC Therapeutics, Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| WO-2015076800-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | claimed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2016-09-29 | — | — | US | disclosed |
| WO-2015076800-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280685-A1 | SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS | BMI1, BAZ2A, BAZ2B | KCNH2 3952/4885SCN5A 3115/4885SCN9A 4295/4885 |
| US-10584115-B2 | Substituted pyridine and pyrazine BMI-1 inhibitors | BMI1, BAZ2A, BAZ2B | KCNH2 3952/4885SCN5A 3115/4885SCN9A 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.